AHL
ALDX icon

Abel Hall LLC’s Aldeyra Therapeutics ALDX Stock Holding History

Abel Hall LLC’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,142
Closed -$25.6K – 963
2026
Q1 		$25.6K Buy
+15,142
New +$66.3K 0.01% 783

Other funds holding ALDX

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Abel Hall LLC's ALDX Position: Q2 2026 in Review

Abel Hall LLC sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 15,142 shares — an estimated $25.6K sold.

Abel Hall LLC first reported a position in ALDX in Q1 2026 and held it in 1 quarter. The position peaked at $25.6K in Q1 2026. 18 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Abel Hall LLC reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Abel Hall LLC sold 15,142 Aldeyra Therapeutics shares in Q2 2026, an estimated $25.6K.
  • Abel Hall LLC first reported a position in Aldeyra Therapeutics in Q1 2026 and held it in 1 quarter.
  • Abel Hall LLC's Aldeyra Therapeutics position peaked at $25.6K in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.